EP1438323A4 - Compositions de meningocoque assorties d'un adjuvant - Google Patents

Compositions de meningocoque assorties d'un adjuvant

Info

Publication number
EP1438323A4
EP1438323A4 EP02800481A EP02800481A EP1438323A4 EP 1438323 A4 EP1438323 A4 EP 1438323A4 EP 02800481 A EP02800481 A EP 02800481A EP 02800481 A EP02800481 A EP 02800481A EP 1438323 A4 EP1438323 A4 EP 1438323A4
Authority
EP
European Patent Office
Prior art keywords
meningocoque
adjuvant
compositions
meningocoque compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02800481A
Other languages
German (de)
English (en)
Other versions
EP1438323A2 (fr
Inventor
Derek O'hagan
Nicholas Valiante
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2002/010869 external-priority patent/WO2002080648A2/fr
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Publication of EP1438323A2 publication Critical patent/EP1438323A2/fr
Publication of EP1438323A4 publication Critical patent/EP1438323A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
EP02800481A 2001-10-03 2002-10-03 Compositions de meningocoque assorties d'un adjuvant Withdrawn EP1438323A4 (fr)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US254438 1988-10-06
US32692901P 2001-10-03 2001-10-03
US326929P 2001-10-03
WOPCT/US02/10869 2002-04-05
PCT/US2002/010869 WO2002080648A2 (fr) 2001-04-05 2002-04-05 Augmentation de l'immunite des muqueuses a la suite d'un amorçage parenteral
US37354702P 2002-04-17 2002-04-17
US373547P 2002-04-17
US38067702P 2002-05-13 2002-05-13
US380677P 2002-05-13
US25443802A 2002-09-24 2002-09-24
US0230423 2002-09-24
WOPCT/US02/30423 2002-09-24
PCT/US2002/031726 WO2003028661A2 (fr) 2001-10-03 2002-10-03 Compositions de meningocoque assorties d'un adjuvant

Publications (2)

Publication Number Publication Date
EP1438323A2 EP1438323A2 (fr) 2004-07-21
EP1438323A4 true EP1438323A4 (fr) 2007-08-01

Family

ID=32601151

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02800481A Withdrawn EP1438323A4 (fr) 2001-10-03 2002-10-03 Compositions de meningocoque assorties d'un adjuvant

Country Status (8)

Country Link
EP (1) EP1438323A4 (fr)
JP (1) JP4522699B2 (fr)
CN (1) CN100354297C (fr)
AU (1) AU2002334844B2 (fr)
BR (1) BR0213119A (fr)
CA (1) CA2462646C (fr)
NZ (1) NZ532274A (fr)
WO (1) WO2003028661A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
DE60328481D1 (de) * 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
CA2493124C (fr) * 2002-08-02 2014-04-29 Glaxosmithkline Biologicals S.A. Vaccin
AU2003299994A1 (en) 2002-12-27 2004-07-29 Chiron Corporation Immunogenic compositions containing phospholpid
ES2461350T3 (es) * 2003-01-30 2014-05-19 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
DE602004020189D1 (de) * 2003-01-30 2009-05-07 Novartis Vaccines & Diagnostic Adjuvante influenza-vakzine
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
JP5557415B2 (ja) 2003-06-02 2014-07-23 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 吸着させたトキソイドおよび多糖類含有抗原を含む微粒子に基づく免疫原性組成物
WO2005081847A2 (fr) * 2004-02-20 2005-09-09 Hybridon, Inc. Reponse immunitaire mucosale puissante induite par des oligonucleotides immunomodulateurs modifies
WO2007013893A2 (fr) * 2004-11-15 2007-02-01 Novartis Vaccines And Diagnostics Inc. Compositions immunogenes contenant un antigene de l'anthrax, des microparticules de polymeres biodegradables, et un adjuvant immunologique contenant un polynucleotide
JP5191740B2 (ja) 2005-01-28 2013-05-08 ガレンバイオ、インコーポレイテッド 免疫学的に活性な組成物
WO2006092607A1 (fr) * 2005-03-02 2006-09-08 The Secretary Of State For Defence Composition pharmaceutique
EP2244695A1 (fr) 2007-12-07 2010-11-03 Novartis AG Compositions utilisées pour induire des réponses immunitaires
CN101559225B (zh) * 2008-04-18 2012-07-11 北京生物制品研究所 脑膜炎球菌疫苗
CA2876495C (fr) 2012-06-21 2023-10-17 Northwestern University Particules conjuguees a des peptides

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1900818A3 (fr) * 1997-11-06 2008-06-11 Novartis Vaccines and Diagnostics S.r.l. Antigènes de Neisserial
WO1999036544A2 (fr) * 1998-01-14 1999-07-22 Chiron S.P.A. Antigenes du $i(neisseria meningitidis)
EP2261347A3 (fr) * 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
AU763975B2 (en) * 1998-07-29 2003-08-07 Novartis Vaccines And Diagnostics, Inc. Microparticles with adsorbent surfaces, methods of making same, and uses thereof
MXPA01003557A (es) * 1998-10-09 2004-04-05 Chiron Corp Secuencias genomicas de neisseria y metodos para su uso.
EP2286792A1 (fr) * 1999-02-26 2011-02-23 Novartis Vaccines and Diagnostics, Inc. Microemulsions avec une surface adsorbante, comprenant une émulsion de microgouttes
JP4812942B2 (ja) * 1999-02-26 2011-11-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル ＣＧモチーフを含むオリゴヌクレオチドを用いるＮｅｉｓｓｅｒｉａ抗原殺菌活性の増強
CA2372235A1 (fr) * 1999-04-30 2000-11-09 Rino Rappuoli Antigenes de neisseria conserves
DK1947187T5 (da) * 2000-02-28 2011-10-24 Novartis Vaccines & Diagnostic Hybrid ekspression af neisserial-proteiner

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
O'HAGAN D T ET AL: "POLY(LACTIDE-CO-GLYCOLIDE) MICROPARTICLES FOR THE DEVELOPMENT OF SINGLE-DOSE CONTROLLED-RELEASE VACCINES", ADVANCED DRUG DELIVERY REVIEWS, AMSTERDAM, NL, vol. 32, 1998, pages 225 - 246, XP000944990, ISSN: 0169-409X *
SINGH M ET AL: "ADVANCES IN VACCINE ADJUVANTS", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 17, no. 11, November 1999 (1999-11-01), pages 1075 - 1081, XP000941305, ISSN: 1087-0156 *
SINGH M ET AL: "Cationic microparticles are an effective delivery system for immunie stimulatory CpG DNA", PHARMACEUTICAL RESEARCH, NEW YORK, NY, US, vol. 18, no. 10, October 2001 (2001-10-01), pages 1476 - 1479, XP002976979, ISSN: 0724-8741 *

Also Published As

Publication number Publication date
NZ532274A (en) 2006-02-24
WO2003028661A3 (fr) 2003-10-09
EP1438323A2 (fr) 2004-07-21
JP2005526697A (ja) 2005-09-08
CN100354297C (zh) 2007-12-12
WO2003028661A2 (fr) 2003-04-10
CA2462646A1 (fr) 2003-04-10
BR0213119A (pt) 2004-12-28
CA2462646C (fr) 2013-02-12
CN1599746A (zh) 2005-03-23
AU2002334844B8 (en) 2003-04-14
JP4522699B2 (ja) 2010-08-11
AU2002334844B2 (en) 2007-08-02

Similar Documents

Publication Publication Date Title
EP1438074A4 (fr) Compositions d'adjuvants
FI20010780A0 (fi) Parannetut koostumukset
PL368370A1 (pl) Kompozycja glifosatu
ATE303787T1 (de) Schergelzusammensetzungen
ATE553775T1 (de) Impstoffzusammesetzung
IS6915A (is) Lyfjablanda
AR028197A1 (es) Composiciones antitranspirantes
PT1139764E (pt) Composicao adjuvante
BR0210619A (pt) composição
IS7081A (is) Lyfjablanda
ATE369830T1 (de) Schweisshemmende zusammensetzungen
ATE314049T1 (de) Schweisshemmende zusammensetzungen
PT1238587E (pt) Composicoes de biopesticidas
EG23126A (en) Novel fungicial compositions
EP1420818A4 (fr) Compositions antigeniques
GB0114532D0 (en) Novel compositions
ITMI20010954A0 (it) Procedimento di iodurazione
NO20032086L (no) Adjuvans kombinasjonsformuleringer
NO20020524L (no) Stabiliserte organisk-peroksid sammensetninger
ITTO20020744A0 (it) Composizione
ITTO20020745A0 (it) Composizione
DE60200786D1 (de) Feste zusammensetzung
ITRC20010003A1 (it) "fumanello"
SE0101369D0 (sv) Free 4 ever
SE0100477D0 (sv) Novel formulation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040420

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20070704

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/385 20060101ALI20070628BHEP

Ipc: A61K 39/095 20060101ALI20070628BHEP

Ipc: A61K 39/02 20060101AFI20070628BHEP

17Q First examination report despatched

Effective date: 20101020

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140501